View in EDS HTML Full Text PDF Full Text

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.

Saved in:
Bibliographic Details
Title: Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Authors: Sharman, Jeff P.1 (AUTHOR) jeff.sharman@usoncology.com, Forero-Torres, Andres2 (AUTHOR), Costa, Luciano J.3 (AUTHOR), Flinn, Ian W.4 (AUTHOR), Inhorn, Lowell5 (AUTHOR), Kelly, Kevin6 (AUTHOR), Bessudo, Alberto7 (AUTHOR), Fayad, Luis E.8 (AUTHOR), Kaminski, Mark S.9 (AUTHOR), Evens, Andrew M.10 (AUTHOR), Flowers, Christopher R.11 (AUTHOR), Sahin, Deniz12 (AUTHOR), Mundt, Kirsten E.12 (AUTHOR), Sandmann, Thomas13 (AUTHOR), Fingerle-Rowson, Günter12 (AUTHOR), Vignal, Charlotte12 (AUTHOR), Mobasher, Mehrdad13 (AUTHOR), Zelenetz, Andrew D.14 (AUTHOR)
Source: Leukemia & Lymphoma. Apr2019, Vol. 60 Issue 4, p894-903. 10p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:10428194
DOI:10.1080/10428194.2018.1515940